https://www.selleckchem.com/pr....oducts/ly3200882.htm
8%) who preferred the oral route had never experienced it before, while this was rare (3.6%) regarding the parenteral route (P = 0.0001). Employment status was associated with preference of the subcutaneous route over the intravenous route of bDMARDs (P = 0.01). Of the 21 patients who had previously experienced both parenteral and oral treatment, 16 (76.2%) preferred the oral route. CONCLUSIONS RA patients preferred to continue treatment with an administration route they have already experienced. However, when choosing an unexperience
Мне нравится
Комментарий
Перепост
